FCGBP inhibits the development of LSCC and cisplatin resistance through the PIGR/JAK2/STAT3 pathway

Abstract

Background: The second most prevalent cancer in the head and neck is laryngeal squamous cell carcinoma (LSCC), and one of the main treatment challenges is cisplatin resistance. In addition to being a tumor suppressor in many types of cancer, IgGFc binding protein (FCGBP) is linked to tumor medication resistance. We looked into the function of FCGBP in LSCC in this work.

Method: FCGBP expression and prognostic analysis were analyzed by GEPIA website. The effects of FCGBP in vivo were validated using the nude mouse xenograft model of mouse LSCC, while the effects of FCGBP in vitro were investigated using half maximal inhibitory concentration (IC50) analysis, colony formation assay, and flow cytometry assay. The mechanism by which FCGBP inhibits cisplatin resistance was studied by knocking down polymeric immunoglobulin receptor (PIGR).

Result: FCGBP is lowly expressed in head and neck squamous cell carcinoma and LSCC cell lines and is associated with poor prognosis. FCGBP can inhibit the viability and proliferation of LSCC cells, and FCGBP can inhibit the resistance of LSCC cells to cisplatin. In addition, FCGBP can regulate the PIGR/JAK2/STAT3 pathway and exert anti-cancer and anti-cisplatin resistance effects through this pathway. In addition, FCGBP can inhibit the growth of LSCC tumors in vivo.

Conclusion: Our findings demonstrated that the FCGBP/PIGR/JAK2/STAT3 axis plays a regulatory role in cisplatin resistance in LSCC, indicating that FCGBP could be a viable target to enhance the therapeutic benefit of cisplatin.